Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma

Annals of Oncology

Volumn 12, Issue 5, 2001, Pages 661-667

  Borchmann, P ^a   Schnell, R ^a   Knippertz, R ^a   Staak, J O ^a   Camboni, G M ^b   Bernareggi, A ^b   Hubel K ^a   Staib, P ^a   Schulz, A ^a   Diehl, V ^a   Engert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Novuspharma SpA   (Italy)

Author keywords

Aza anthracenedione; BBR 2778; Non Hodgkin's lymphoma; Pharmacokinetics; Phase I

Indexed keywords

6,9 BIS[(2 AMINO)ETHYLAMINO]BENZO[G]ISOQUINOLINE 5,10 DIONE DIMALEATE; ANTHRAQUINONE DERIVATIVE; BBR 2778; DOXORUBICIN; IDARUBICIN; MITOXANTRONE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; HUMAN; MALE; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 0034988022     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011139016294     Document Type: Article

References (18)

1. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy
2. Strategies for prevention of anthracycline cardiotoxicity
3. Current concepts: Doxorubicin induced cardiomyopathie
4. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids
5. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: Relationship with binding mode and antitumor activity
6. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza and 2-aza-oxode-anthrace-nedione derivates
7. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells
8. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse
9. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute Sponsored Working Group
10. Phase I and pharmaco-kinetic study of BBR 2778, a novel aza-anthracenedione, in patients with advanced solid tumours
11. Pharmacokinetics and metabolism of mitoxantrone. A review
12. Clinical kinetics of 1.4-dihydroxy-5,8-bis-{[2 -[(2-hydroxyethyl)amino]ethyl]amino}-9,10-anthracenedione
13. Pharmacology of mitoxantrone: Mode of action and pharmacokinetics
14. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma
15. Pharmacokinetics of [14C]BBR 2778 in male CD2F1 mice after a single intravenous bolus
16. Pharmacokinetics and tissue distribution of [14C]BBR 2778 in male rats after single intravenous infusion
17. Treatment of primary progressive lymphoma: Is there a chance for cure?